BeiGene takes a hit af­ter his­toric $903M Hong Kong IPO with neg­a­tive biotech sen­ti­ment

The first day of its sec­ondary list­ing in Hong Kong has proven slight­ly dis­ap­point­ing for BeiGene.

The Bei­jing-based can­cer drug­mak­er closed its trad­ing de­but down …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER